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Both iron dyshomeostasis and N-methyl-D-aspartate receptors (NMDARs)-mediated
neurotoxicity have been shown to have an important role in neurological diseases
such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Evidence proved that
activation of NMDARs could promote iron overload and iron-induced neurotoxicity by
enhancing iron importer divalent metal transporter 1 (DMT1)-mediated iron uptake and
iron releasing from lysosome. Also, iron overload could regulate NMDARs-mediated
synaptic transmission. This indicates that there might be a possible relationship between
iron and activation of NMDARs in neurological diseases. Understanding this interaction
between iron and activation of NMDARs may provide new therapeutic avenues for a
more targeted neurotherapeutic strategy for these diseases. Therefore, in this review
article, we will describe the dysfunction of iron metabolism and NMDARs in neurological
diseases including PD and AD, and summarize the new insight into the mechanisms
underlying the interaction between iron and activation of NMDARs.
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INTRODUCTION
Iron is an important cofactor in many proteins such as heme-containing proteins and
iron-containing enzymes. It is required for many physiological processes for life (Zucca et al.,
2015). In the central nervous system (CNS), iron also participates in myelin synthesis, development
of dendritic spines in the hippocampus and synthesis of neurotransmitters including monoamine
transmitters and gamma-aminobutyric acid (GABA; Li, 1998; Jorgenson et al., 2003; Todorich
et al., 2009; Zucca et al., 2015; Bastian et al., 2016). However, excess iron is toxic due to its ability
to produce cytotoxic hydroxyl radicals, which could cause damages to proteins, nucleic acids and
cell membranes (Whitnall and Richardson, 2006). Therefore, intracellular iron metabolism is
tightly regulated. There are two pathways for iron uptake: the classical transferrin (Tf)-mediated
iron uptake pathway and the non-Tf bound iron (NTBI) uptake pathway (Qian and Shen, 2001).
Traditionally, the Tf-transferrin receptor 1 (Tf-TfR1) pathway is considered as major pathway
for cellular iron uptake in the brain. Divalent metal transporter 1 (DMT1) is identified as the
main NTBI pathway, responsible for ferrous iron uptake. There are four DMT1 mRNA isoforms:
N-terminus (1A, 1B) generated from alternative promoters with subsequent, exclusive splicing
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of the respective first exon to exon 2 and C-terminus splice
variants (+iron-responsive element (IRE), −IRE) due to
alternative splice mechanisms (Hubert and Hentze, 2002).
DMT1 + IRE contains an IRE in the 3′-untranslated region
(UTR) and DMT1 − IRE has no IRE. Additionally, 1A/DMT1 is
predominantly expressed in kidney and duodenum and
1B/DMT1 is ubiquitously expressed in the peripheral organs
and brain (Hubert and Hentze, 2002). Ferroportin 1 (FPN1),
also known as metal transport protein1 (Abboud and Haile,
2000) or iron-regulated transporter 1 (IREG1) is the only known
iron transporter responsible for cellular iron export (Ganz,
2005). Disturbance in iron metabolism plays a key role in the
pathogenesis of neurodegenerative disorders such as Parkinson’s
disease (PD) and Alzheimer’s disease (AD) (LaVaute et al.,
2001; Lieu et al., 2001; Perez et al., 2008; Zhu et al., 2009).
Elevated iron levels were found in the substantia nigra (SN) in
PD patients (Sofic et al., 1988). Studies also showed that iron
accumulation was observed in the hippocampus and cerebral
cortex in AD patients (Piñero et al., 2000, 2001; Altamura and
Muckenthaler, 2009). Increased import, decreased export or
redistribution of intracellular iron might be responsible for iron
metabolism disturbance in these diseases, which may increase
the vulnerability of neurons to iron.
Glutamate is the major excitatory neurotransmitter in the
CNS, exerting its functions by binding to different receptors.
Among them, N-methyl-D-aspartate receptors (NMDARs) are
cation channels that mediate entry of Na+ and Ca2+ ions and are
activated by the co-agonists glutamate (or NMDA) and glycine or
D-serine. There are several subunits of NMDARs: NR1, NR2A,
NR2B, NR2C and NR2D and NR3. Among them, NR1 is a
fundamental subunit of the receptor. Appropriate activation of
NMDARs plays a critical role in physiological functions such
as excitatory neurotransmission, synaptic plasticity (Carvajal
et al., 2016). However, excitotoxicity induced by excessive
activation of NMDARs contributes to pathological changes in
the CNS (Ambrosi et al., 2014; Gonzalez et al., 2015). Influx
of Ca2+ through NMDARs might lead to neuronal loss in
several neurodegenerative diseases such as PD and AD (Hynd
et al., 2004). NMDARs have both synaptic and extrasynaptic
locations. One hypothesis posits that synaptic NMDARs were
neuroprotective and extrasynaptic NMDARs were neurotoxic
(Hardingham and Bading, 2010). The death signaling induced
by extrasynaptic NMDARs or relocalization of NMDARs to
extrasynaptic sites has been shown to contribute to pathology
of neurodegenerative diseases (Bading, 2017). Fine-tuning might
provide a promising operation to optimize the activity of the
glutamatergic system in order to maintain normal function
of neurons (Köles et al., 2016). Activation of NMDARs as
well as iron deposits in neurological diseases including PD
and AD suggest that there might be a correlation between
iron deposition and activation of NMDARs. Therefore, in
this article, we reviewed the studies about the involvement of
iron dyshomeostasis and NMDARs-mediated neurotoxicity in
PD and AD. We then described the advanced knowledge on
interaction of iron and NMDARs activation. This will provide
implications for understanding pathology of these neurological
diseases.
DYSFUNCTION OF IRON METABOLISM
AND NMDARs IN PD
PD is a common neurodegenerative disorder characterized by
loss of dopamine (DA) neurons in the SN pars compacta
(SNpc), resulting in depletion of DA in the striatum (Parkinson,
2002; Hornykiewicz, 2008). Although the etiology of PD has
not been clarified until now, iron accumulation and excitatory
neurotoxicity are considered as contributing factors to the
etiology of PD. It has become increasingly evident that elevated
iron levels in the SNpc play a key role in the degeneration of DA
neurons in PD (Jiang et al., 2016; Muñoz et al., 2016). Nigral iron
levels increased with age, and PD patients showed an even greater
increase, which correlates with clinical PD status (Wu et al., 2014;
Du G. et al., 2016). Experimental evidence also showed that iron
was involved in the degeneration of SNpc dopaminergic neurons
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and
6-hydroxydopamine (6-OHDA)-induced animal models of PD
(Salazar et al., 2008; Jiang et al., 2010). Mechanisms underlying
iron-induced neurodegeneration of DA neurons have been
reported: First, iron participates in Fenton reaction to generate
·OH, which could damage proteins, nucleic acids and cell
membranes (Mohanakumar et al., 1994). Second, iron-induced
α-synuclein oligomers can form ion-permeable pores in lipid
bilayers and give rise to α-synuclein-dependent toxicity in
neuronal cells (Kostka et al., 2008). Our previous studies
also showed iron could promote α-synuclein aggregation (He
et al., 2013). Third, iron overload induced mitochondrial
fragmentation via increasing intracellular calcium (Ca2+) and
activated calcineurin via Ca2+/calmodulin and Ca2+/calpain
pathways. This mitochondrial fragmentation and neuronal cell
death could be rescued by chelation of intracellular Ca2+ (Lee
et al., 2016). Recently, it was reported that ferroptosis, an
iron-dependent regulated cell death process, is an important
cell death pathway for DA neurons in PD (Do Van et al.,
2016).
A recent research showed that increase in DMT1 expression,
rather than TfR1 and Fpn1 expression might be partly
responsible for age-dependent increase in brain iron (Lu et al.,
2016). This indicated the importance of DMT1 in age-induced
iron overload. Our previous studies showed that increased
expression of DMT1 + IRE and decreased expression of
FPN1 were responsible for nigral-specific iron accumulation in
PD models (Wang et al., 2007; Jiang et al., 2010; Song et al., 2010).
DMT1 was found in the SNpc and associated predominantly with
neuromelanin-containing DA neurons. It was consistently less
intense in DA neurons of the ventral tegmental area (VTA) than
in those of the SNpc in the same tissue sections of human brain
older than 60 years (Salazar et al., 2008). In addition, postmortem
studies have shown an increase of DMT1 in the SN of PD patients
(Salazar et al., 2008). And a mutation in DMT1 that impaired
iron transport protected rodents against parkinsonism-inducing
neurotoxins MPTP and 6-OHDA (Salazar et al., 2008). Recent
study demonstrated that DMT1 polymorphisms might be a risk
factor for PD (Saadat et al., 2015). This indicated that higher
DMT1 expression and consequently higher iron levels in nigral
DA neurons might contribute to increased vulnerability of nigral
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DA neurons to PD-related neurotoxins (Huang E. et al., 2004).
The mechanisms underlying the expression of iron transporters
DMT1 + IRE and FPN1 are IRE/iron regulatory proteins (IRPs)-
dependent in 6-OHDA-induced PD models and IRE/IRPs-
independent in MPP+-treated dopaminegic cells (Zhang et al.,
2009; Jiang et al., 2010). In addition, ceruloplasmin (CP) is the
strongest ferroxidase to stabilize iron exporter FPN1. It was
reported that the activity of CP in PD brains was reduced in SN
(Ayton et al., 2013). In CP-knockout mice, iron overload was
found in several tissues, including the brain (Kaneko et al., 2008).
In our previous report, we also showed that decreased expression
of CP in the SN was involved in the nigral iron accumulation
of 6-OHDA-induced PD rats (Wang et al., 2015). These results
suggested that CP might also play an important role in iron
deposit in PD.
In addition, NMDARs-mediated excitotoxicity also
contributed to the progressive degeneration of nigral DA
neurons in PD (Ambrosi et al., 2014). Research has showed
that ligand-gated ion channel NMDARs were vital in the
glutamate-induced excitotoxicity in primary dopaminergic cell
culture (Oster et al., 2014). Furthermore, glutamate exposure
induced Parkin accumulation at mitochondria in a calcium-
and NMDARs-dependent manner (Van Laar et al., 2015). It
has been confirmed that SNpc DA neurons express functional
triheteromeric NMDARs composed of NR1, NR2B and NR2D
subunits (Jones and Gibb, 2005). A selective decrease of
NR1 pan mRNA levels in layer IV of frontal cortex was found
in PD patients (Meoni et al., 1999). However, NR1 expression
increased in surviving SN DA neurons from PD brains compared
with neurons from controls (Schiemann et al., 2012). Meanwhile,
intracellular Ca2+ overload triggered by activation of NMDARs
is believed to be responsible for inducing of nitric oxide synthases
(NOS) activity, affecting mitochondrial integrity and functions
(Yamauchi et al., 1998; Sattler and Tymianski, 2000). It has
been reported that NMDARs antagonists were considered as
potential therapies for patients with PD (Little and Brown, 2014).
Among the NMDARs antagonists, memantine has been reported
to preferentially blocks extrasynaptic NMDARs of SNpc DA
neurons in slices of rat midbrain using whole-cell patch-clamp
recordings (Wu and Johnson, 2015). This selective effect on
NMDARs might be protective due to the neurotoxic effect of
extrasynaptic NMDARs.
DYSFUNCTION OF IRON METABOLISM
AND NMDARs IN AD
AD is a progressive neurodegenerative disorder, clinically
characterized by a progressive loss of cognitive abilities and
dementia, which is closely related to a degree of neuronal
and synaptic loss (Selkoe, 1996; Hardy, 1997; Mattson, 1997).
The key features of the disease are the accumulation of
extracellular amyloid-β (Aβ) plaques and neurofibrillary tangles
inside neurons. Although genetic and non-genetic factors are
involved in the etiology of AD, the exact reason is still unknown.
Increasing evidence suggests that iron might play an important
role in the development or progression of AD (Mandel et al.,
2007; Ward et al., 2014; Belaidi and Bush, 2016; Van Bergen et al.,
2016). The first evidence is that iron accumulates in the same
brain regions which are characterized by Aβ deposition such as
hippocampus, parietal cortex and motor cortex in AD patients
(Dedman et al., 1992; Good et al., 1992). High levels of iron
have also been reported in the amyloid plaques in PS/amyloid
precursor protein (APP) and APP [V717I] transgenic mice
(Falangola et al., 2005), resembling those seen in the brains of
AD patients. In addition, higher cortical iron was associated with
increased Aβ-plaque-load in mild cognitive impairment (MCI;
Van Bergen et al., 2016). Another important link between iron
and AD is based on the observation that APP expression is
iron-regulated. APP is a single transmembrane metalloprotein
that is cleaved to generate the 40–42-amino-acid Aβs by β- and
γ-secretases. The existence of a functional IRE in the 5′- UTR
of APP mRNA makes it possible to be controlled at the level
of mRNA translation by the action of IRE/IRP’s response to
iron (Rogers et al., 2002). This implied that high intracellular
iron levels could cause increased APP translation and Aβ
formation via this mechanism. In addition, iron could induce
Aβ precipitation (Mantyh et al., 1993; Huang X. et al., 2004)
and significantly enhance the toxicity of Aβ in cultured neuronal
cells, whereas iron chelators protect the neurons from Aβ toxicity
(Schubert and Chevion, 1995). This provided a direct link
between excessive iron and loss of neuronal function seen in AD
patients.
However, the underlying mechanisms involved in disturbance
of iron homeostasis in AD brain remain unclear. It is reported
that Aβ is a metalloprotein that binds transition metal ions
through three histidine residues (His6, His13 and His14) located
in the N-terminal domain (Nakamura et al., 2007; Altamura and
Muckenthaler, 2009). And other protein that accumulates in AD
such as tau protein also possesses metal-binding sites (Perry et al.,
2003). These might account for the iron accumulation in the
affected brain regions in AD. Furthermore, it is reported that
DMT1 was colocalized with Aβ in the plaques of postmortem
AD brain and the levels of DMT1 was significantly increased
in the cortex and hippocampus in APP/PS1 transgenic mouse
model compared with wild type-control (Zheng et al., 2009). And
the mean serum p97 concentration was elevated 3- to 4-fold in
patients with AD as compared to non-AD dementia and normal
controls (Kim et al., 2001). In addition, HO-1 is increased in
neurofibrillary tangles, senile plaque neurites, granulovacuolar
degeneration and neuropil threads in human AD brains (Smith
et al., 1994; Perry et al., 2003), suggesting the redistribution of
iron due to release from heme proteins in affected areas of the
AD brain.
NMDARs–mediated excitotoxicity also contributed to the
pathology of AD. Evidence proved that impaired glutamate
uptake in astrocytes and neurons in AD can lead to increased
concentrations of glutamate at the synapse, which can
subsequently trigger NMDARs–mediated excitotoxicity via
increase of intracellular Ca2+ concentrations (Greenamyre et al.,
1988; Tong et al., 2017). It has been shown that extrasynaptic
NMDARs were largely associated with NMDARs-mediated
excitotoxicity in AD (Hardingham and Bading, 2010). Prolonged
activation of extrasynaptic NMDARs increases APP processing,
leads to neuronal Aβ release, and ultimately results in AD
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pathology (Bordji et al., 2010). It has been reported that an open
channel blocker memantine could preferentially antagonize
excessively activated NMDARs (Lipton, 2004). In vitro and
in vivo studies have demonstrated the neuroprotective effect of
memantine in AD models. Memantine could prevent oligomeric
Aβ-induced oxidative stress in mature hippocampal neurons (De
Felice et al., 2007). More interestingly, memantine decreased the
levels of secreted APP and Aβ peptide in human neuroblastoma
cells (Ray et al., 2010) and lowered cortical levels of Aβ1–42 in
APP/PS1 transgenic mice (Alley et al., 2010). This indicated the
important role of excessively activated NMDARs in AD.
INTERACTION OF IRON AND NMDARs
ACTIVATION
NMDARs Activation Promoted Iron
Accumulation
Results revealed that activation of NMDARs significantly
promoted Fe2+ entry into cells (Cheah et al., 2006). It
was reported that NMDARs activation might promote iron
accumulation by accelerating DMT1-mediated iron influx
(Cheah et al., 2006), enhancing iron releasing from lysosome and
regulation the expression of DMT1 (White et al., 2016). Elevated
intracellular iron then aggravated iron-induced cell damage.
NMDARs Activation Increased NTBI Influx
It has been demonstrated that ferrous iron could block the
influx of Ca2+ across NMDARs channels in cultured neurons
(Nakamichi et al., 2004). This indicated that Fe2+ competed
with Ca2+ for NMDARs to enter primary neurons. This iron
entry can be harmful for neurons during aging due to increased
NTBI levels. An investigation with interest to the involvement
of NMDARs in NTBI influx pathways showed that activation
of NMDARs significantly promoted Fe2+ entry into cells
using fluorescence-based single cell analysis in rat hippocampal
primary cultures (Pelizzoni et al., 2011). This elevation of iron
was accompanied by a corresponding increase in reactive oxygen
species (ROS) production and higher susceptibility of neurons to
death.
Another investigation demonstrated a novel signaling cascade
for glutamate in regulating iron uptake in the brain (Cheah
et al., 2006). It is increasingly appreciated that glutamate via
NMDARs triggers calcium influx, then activates neuronal NOS
(nNOS) to produce NO, which causes excitability toxicity
(Guix et al., 2005; Cheah et al., 2006; Chen et al., 2013;
Courtney et al., 2014). Research has identified a signaling cascade
whereby NMDARs regulated iron homeostasis (Cheah et al.,
2006). Their results showed that the activation of NMDARs
could increase intracellular iron levels in PC12 cells via NO-
Dexras1-peripheral benzodiazepine receptor-associated protein
7 (PAP7)-DMT1 signaling cascade to enhance iron uptake
(Cheah et al., 2006). Additionally, chelation of intracellular iron
blocked formation of free radicals in brain cultures and also
markedly attenuated NMDA neurotoxicity (Cheah et al., 2006).
Furthermore, subsequent investigation showed that Dexras1 was
required for NMDA-elicited neuronal toxicity via NO and
iron influx (Chen et al., 2013). This implies that NMDA-NO
activation-induced iron uptake might play an important role
in neurotoxicity and misregulation of this pathway might
participate in iron accumulation in PD. It has been shown
that nNOS binding to CAPON leading to NO delivery to
Dexras1 and S-nitrosylation of Dexras1. Then S-nitrosylation of
Dexras1 could enhance iron uptake by regulating the function
of iron importer DMT1. It was also reported that Dexras1 could
be phosphorylated by protein kinase A (PKA) on serine 253.
This PKA activation reduced Dexras1 S-nitrosylation, leading
to an inhibition of iron influx (Chen et al., 2015). This
indicated the important role of Dexras1 S-nitrosylation in iron
uptake. In addition, PAP7 might presumably serve as a scaffold
delivering Dexras1 into proximity to DMT1 (Cheah et al., 2006).
However, another research showed that PAP7 played a role in
cellular iron metabolism. They found that PAP7 was internalized
in parallel with the internalization of DMT1 following iron
feeding. And downregulated PAP7 expression in K562 cells
with small interfering RNA led to downregulation of DMT1
(IRE) protein but not DMT1 (−IRE) mRNA. However,
they did not measure iron uptake after downregulation of
PAP7 expression. The levels of TfR1 and ferritin were not
affected following transfection with siPAP7, indicating that
the intracellular iron level might not change (Okazaki et al.,
2012). Moreover, they also reported that overexpression of
PAP7 had no effect on DMT1 (IRE) expression which is
consist with the results of Cheah et al. (2006). Further
research should be conducted to figure out the mechanisms
underlying the effect of PAP7 on DMT1 and DMT1-induced iron
uptake.
Rhes (Dexras2), a homolog of Dexras1, is a highly
conserved small GTP binding protein belonging to the Ras
superfamily. Rhes shares 67% identity with Dexras1. Although
the physiological role of Rhes is not fully understood, results
showed that Rhes physiologically interacted with PAP7 and
participated in DMT1-induced iron uptake via pathway similar
to Dexras1 (Choi et al., 2013). However, the mechanisms
underlying the effect of Rhes on DMT1-induced iron uptake
are different from Dexras1. They showed that Rhes was not
S-nitrosylated after NO-treatment, however was phosphorylated
by PKA at serine-239 (Choi et al., 2013). Rhes is selectively
localized to the corpus striatum (Errico et al., 2008), so
might involved in NMDARs-induced iron entry into the
striatal neurons and maintain striatal iron homeostasis via
PKA-Rhes-DMT1 pathway. In addition, striatum received
nigral dopaminergic synapses projection and is responsible for
movement balance. Imbalance of iron metabolism in striatum
might contribute to the degeneration of striatal neurons and
dysregulation of dopaminergic function in the striatum due to
iron-induced oxidative stress, then affecting motor function.
NMDARs Activation Enhanced Iron Releasing from
Lysosome
In fact, Dexras1 also could regulate TfR-mediated iron uptake
as well as NTBI uptake (DMT1-mediated iron uptake) (Cheah
et al., 2006). However, the exact mechanisms underlying this
effect are not elucidated. Subcellular localization experiments
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showed that DMT1 + IRE had higher surface expression
and was internalized from the plasma membrane with slower
kinetics than DMT1 − IRE. And it was not efficiently recycled
and was targeted to lysosomes. While DMT1 − IRE is
efficiently sorted to recycling endosomes upon internalization
(Lam-Yuk-Tseung and Gros, 2006). This implicated that
different isoforms of DMT1 might have different functions
on regulation of the subcellular localization of Fe2+ transport.
As lysosomal iron serves as a main source for intracellular
iron and DMT1 plays a role in iron recycling from lysosome
to cytoplasm, DMT1-mediated iron release from lysosome
might be responsible for increased intracellular iron levels.
Findings from patch-clamping of individual lysosomes showed
that they could transmit iron through their membrane
(Dong et al., 2008). Recently, an investigation confirmed that
the Dexras1/ACBD3(PAP7)/DMT1 complex was located on
the lysosomes (White et al., 2016). Collapsing the proton
gradient or blocking DMT1 channel both could reduce
cytosolic iron pool (White et al., 2016), indicating that
Dexras1/ACBD3/DMT1 complex played roles in iron release
from lysosome. Therefore, NMDA activation not only led to
Dexras1/DMT1 mediated increase in iron uptake, but also
enhanced Dexras1-dependent iron release from lysosome.
NMDARs Activation Increased DMT1 Expression
Activation of NMDARs not only could affect the iron uptake
function of DMT1, but also could regulate its expression. It
has been reported that mRNA expression of DMT1-1B and
DMT1 + IRE increased after 5 min exposure of 50 µM
NMDA to primary hippocampal cultures, but not mRNA
expression of DMT1 − IRE (Haeger et al., 2010). NMDA
also enhanced DMT1 protein expression, which was abolished
by the transcription inhibitor actinomycin D and NMDARs
antagonist MK-801 (Haeger et al., 2010). This stimulation
on iron entry pathway via DMT1 could ensure an adequate
iron supply. This is of potential importance because iron
deficiency hinders learning processes and impairs cognitive
performance (Carlson et al., 2009; Muñoz et al., 2011; Estrada
et al., 2014). This implicated that NMDARs-activation stimulated
expression of the iron transporter DMT1-1B + IRE, which
presumably played a significant role in hippocampal spatial
memory formation. Interestingly, both excessive activation of
NMDARs and upregulation of DMT1 were contributing factors
in degeneration of DA neurons in PD, indicating the link
between activation of NMDARs and upregulation of DMT1 in
PD. Further studied should be conducted to elucidate this
possibility and the underlying mechanisms.
NMDARs-Induced Co-Activation of ATP-Sensitive
Potassium (KATP) Channels Might Promote Iron Influx
via DMT1
KATP channel was first discovered by Akinori Noma in cardiac
myocytes and was demonstrated to be important for regulation
of cellular energy metabolism in the control of membrane
excitability (Noma, 1983). Liss et al. (2005) provided evidence
that selective activation of KATP channels of DA midbrain
neurons in the SN was a potential mechanism for the selective
degeneration of DA neurons in PD. Increased activity of KATP
channels due to metabolic stress leads to membrane potential
hyperpolarization and reduced SN DA activity (Liss et al., 2005).
Although in adult mice KATP channels in DA neurons of both SN
and VTA are formed by the same subunits (four Kir6.2 subunits
and four regulatory SUR1 subunits), the activation of nigral
KATP channels of DA neurons was responsible for the selective
degeneration of DA neurons in PD (Liss et al., 2005). Moreover,
genetic inactivation of the pore-forming subunit Kir6.2 of
KATP channels induced a selective rescue of SN DA (but not
VTA DA) neurons in MPTP-induced PD models (Liss et al.,
2005). This indicated that activation of nigral KATP channels
contributed to the selective degeneration of DA neurons in
the SN.
It is reported that the activation of KATP channels induced
hyperpolarization of the membrane potential of DA neurons
in the SN following MPP+ treatment (Liss et al., 2005).
Furthermore, it was reported DMT1-mediated iron transport
was driven at higher rates of hyperpolarized potentials (Gunshin
et al., 1997). This makes the possibility that the hyperpolarization
of cell membrane induced by activation of KATP channels
might increase DMT1-mediated iron transport, and enhance
iron influx into the DA neurons. Results in our experiments
demonstrated that activation of the KATP channels in the
DA cells caused hyperpolarization of the cell membrane and
subsequently enhanced ferrous iron uptake function (Du X. et al.,
2016). Results showed that activation of KATP channels resulted
in increased free iron levels in the SK-N-SH cells and this
was partially blocked by DMT1 knockdown. Further studies
showed that activation of KATP channels by diazoxide prolonged
Fe2+-evoked currents in DMT1-transfected HEK293 cells using
whole cell patch clamp recordings (Du X. et al., 2016). And
inhibition of the KATP channels protected the DA neurons
from the ferrous iron insult (Du X. et al., 2016). These
results suggest that the activation of KATP channels could
enhance DMT1-mediated iron uptake, resulting in an increased
intracellular iron contents and oxidative stress, and ultimately
cell damage.
It has been proved that there is a relationship between
NMDARs and KATP channels. Elevated mRNA expressions
of KATP channels and NMDARs subunits were found in
human SN DA neurons from PD patients (Schiemann
et al., 2012). NMDARs stimulation in vitro induced the
co-activation of KATP channels in subthalamic neurons (Shen
and Johnson, 2010). Activity of KATP channels in medial
DA neurons of the SN enabled NMDA-mediated bursting
in vitro and in vivo in anesthetized mice (Schiemann et al.,
2012). Furthermore, activation of KATP channels in already
metabolically challenged SN DA neurons could promote
excitotoxicity and increase NMDARs-mediated calcium loading
(Schiemann et al., 2012). Calcium-triggered ROS production
from mitochondria in turn activated KATP channels in highly
vulnerable SN DA neurons (Liss et al., 2005). In addition,
NMDARs-mediated NO production might activate KATP
channels in large DRG neurons via direct S-nitrosylation of
SUR1 subunit (Kawano et al., 2009). The link of KATP channels
and DMT1 indicated that co-activation of NMDARs and KATP
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FIGURE 1 | Possible interaction between N-methyl-D-aspartate receptors (NMDARs) activation and iron overload. NMDARs activation might promote
divalent metal transporter 1 (DMT1)-mediated iron influx via protein kinase A (PKA)-Rhes-DMT1, NO-Dexras1-peripheral benzodiazepine receptor-associated protein
7 (PAP7)-DMT1 signaling cascade pathway and enhance iron releasing from lysosome, then aggravated iron-induced cell damage. In addition, iron overload might
stimulate calcium release from endoplasmic reticulum (ER). This indicated that glutamate-induced neurotoxicity and iron participated to a vicious cycle of neuronal
death.
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channels could affect iron uptake function of DMT1, which
might contribute to iron accumulation and the degeneration
of neurons in neurological diseases. Further investigation
should be conducted in the future to reveal the underlying
mechanisms.
Iron Affected NMDARs-Mediated Synaptic
Transmission
It was reported that iron has an effect on NMDARs-
mediated synaptic plasticity. Investigation demonstrated that
glutamatergic neurotransmission pathways were regulated by
dietary iron (Han and Kim, 2015). They showed that NMDARs
were significantly elevated in the prefrontal cortex and
hippocampus of iron-loaded rats. These findings indicate
the important role of iron in learning and memory via
regulation NMDARs-mediated neurotransmission. In addition,
study showed that intracellular iron signaling could modulate
neuronal excitability in the hippocampus (White et al., 2016).
They showed that iron was released in neurons from lysosome
can regulate NMDARs mediated glutamatergic excitability via
PKC/Src/NR2A pathway (White et al., 2016). This indicates
that iron can act in a feedback manner to modulate NMDA
function and thus maintain the excitability of neurons in
normal condition. In addition, NMDARs activation induce rapid
opening of Ca2+ channel across cell membranes, followed by
an increase in free Ca2+ ions in the cytoplasm and subsequent
signaling cascade in the CNS (Paul and Connor, 2010).
Hippocampal neurons require iron to generate RyR-mediated
calcium signals after NMDARs stimulation, which in turn
promotes ERK1/2 activation, an essential step of sustained LTP
(Muñoz et al., 2011). It was reported that iron stimulated
RyR-mediated Ca2+ release from endoplasmic reticulum (ER)
in PC12 cells (Múñoz et al., 2006). Further study showed that
iron-induced ROS generation is required for RyR-mediated
Ca2+ release for long-term potentiation in primary hippocampal
neurons (Muñoz et al., 2011).
However, evidence has also proved that iron was
involved in glutamate excitotoxicity (Yu et al., 2009). As is
known that glutamate excitotoxicity could be induced by
threohydroxyaspartate (THA), which could inhibit glutamate
uptake and lead to accumulation of synaptic glutamate and
over stimulation of the postsynaptic receptors. It was found
that increased iron level was involved in THA-induced
glutamate excitotoxicity in rat spinal cord tissue (Yu
et al., 2009). And iron chelator deferoxamine (DFO) could
completely prevent THA-induced motor neuron degeneration.
Importantly, NMDARs inhibitor MK-801 could inhibit
glutamate and hypoxia/reperfusion-mediated damage, but
not the kainate/AMPA antagonist CNQX (Yu et al., 2009). This
supports the idea that iron contributed to glutamate-induced
excitotoxicity via NMDARs and regulation of iron level might
be an effective strategy for protection against glutamate-induced
excitotoxicity. Therefore, iron is required for NMDARs-
mediated synaptic plasticity in physiologic conditions. However,
iron overload might promote NMDARs-mediated excitotoxicity
possibly by enhancing RyR-mediated Ca2+ release and calcium-
induced cell damage. Further studies should be conducted to
investigate this possibility and the underlying mechanisms.
CONCLUSION AND PERSPECTIVES
In this review article, we describe the possible relationship
between NMDARs activation and iron deposit, which both
contributed to the pathogenesis of neurological diseases
including PD and AD. NMDARs activation might promote
iron accumulation by enhancing DMT1-mediated iron influx,
stimulating iron releasing from lysosome, and regulating
DMT1 expression, thus aggravating iron-induced cell damage.
On the other hand, iron overload might aggravate NMDARs-
mediated glutamate excitotoxicity. This suggests that glutamate-
induced neurotoxicity and iron participate to a vicious cycle
of neuronal death (Figure 1). Therefore, regulation of iron
levels might be effective for protection against glutamate-induced
excitotoxicity and NMDARs might be a potential target for
the treatment of iron-induced neurodegenerative processes. The
drug discovery strategy is being oriented toward the development
of new molecules targeting both iron overload and activation
of NMDARs. However, NMDARs-mediated excitotoxicity and
iron deposit were also reported in other neurological diseases
such as stroke, Huntington’ disease (Carvajal et al., 2016; Li and
Reichmann, 2016; Petrova et al., 2016). The exact mechanisms
underlying interaction between NMDARs activation and iron
accumulation in these diseases should be conducted in the future.
The future of this research might have significant impact on the
clinical treatment of these neurological diseases.
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